Approved by the FDA in 2010, Menveo (serogroups A, C, Y, and W-135) conjugate vaccine approval was based on safety and immunogenicity studies reporting the vaccine to be non-inferior to the Menactra (MCV4/ MenACWY-D) conjugate vaccine. As with the Menactra vaccine, no vaccine efficacy studies were completed at the time of licensure, nor had any studies determined whether or not the vaccine could reduce or eliminate nasopharyngeal carriage.
Shortly after FDA licensure, the ACIP recommended Menveo for use when meningococcal vaccination was indicated.9
